Safety Profiles of Bispecific Antibodies for RRMM

Key Takeaways

• Bispecific therapies for RRMM often lead to CRS and ICANS, necessitating careful monitoring and management to mitigate these immune-related adverse events.
• Increased infection risks are a significant concern with bispecific therapies, requiring proactive measures to prevent and manage infections in patients.
• Talquetamab exhibits unique toxicities, including nail-related issues like paronychia, skin-related toxicities such as rash, and oral-related toxicities like dysgeusia.
• Effective management of talquetamab's unique toxicities is crucial to ensure patient adherence and optimize therapeutic outcomes.